Navigation Links
Fovea Pharmaceuticals to be Acquired by sanofi-aventis
Date:10/1/2009

PARIS, Oct. 1 /PRNewswire/ -- Fovea Pharmaceuticals announced today that it has entered into a binding agreement with sanofi-aventis to sell 100% of its share to sanofi-aventis. Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to back of the eye diseases. The deal is valued to a total of euro 370M, including an immediate upfront payment and subsequent milestone payments related to the progress of the clinical compounds. The closing of the transaction is expected to occur in the 4th quarter of 2009.

Fovea was created in 2005 by Professeur Jose A. Sahel, Bernard Gilly and Pierre Belichard, with the initial seeding of Sofinnova Partners in Paris. It successfully raised two rounds of funding in November 2005 and February 2008, from a syndicate of pan-european investors including Sofinnova Partners, Abingworth Management, Forbion Capital Partners, The Wellcome Trust, GIMV, Credit Agricole Private Equity and Vesalius BioCapital.

Fovea has rapidly built a pipeline of products: FOV 1101, an eye drop, fixed dose combination of prednisolone and cyclosporine, currently in phase II for the treatment of persistent allergic conjunctivitis, FOV 2302, an intravitreal formulation of a plasma kallikrein inhibitor, in phase I for the treatment of Retinal Vein Occlusion induced macular edema and FOV 2304, a potent antagonist of bradykinin B1 receptor, active by eye drop, scheduled to enter in phase I by November 2009 for the treatment of diabetic macular oedema.

"Our team is proud and extremely pleased to join sanofi-aventis, as it will provide the necessary resources and expertise needed to continue to aggressively build the ophthalmology franchise and demonstrate the efficacy of our products through regulatory clinical development," commented Bernard Gilly, President and Chief Executive Officer of Fovea Pharmaceuticals. "It also demonstrates that strong science combi
'/>"/>

SOURCE Fovea Pharmaceuticals SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
2. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
3. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
4. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
5. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
6. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
8. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
9. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
10. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
11. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... New York , September 30, 2014 ... - Global Industry Analysis, Market Size, Share, Growth and ... is expected to be worth USD 20.8 billion in ... billion in 2017, growing at a CAGR of 7.3% ... fundamental elements needed for various health purposes, especially to ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
(Date:9/30/2014)... SAN DIEGO , 30. September ... Logo - http://photos.prnewswire.com/prnh/20130430/LA01948LOGO ... ein Medizintechnikunternehmen, das ein minimal-invasives 3D-Herzkammer-Bildgebungs- ... der Ursachen entwickelt, die zu komplexen ... aufrechterhalten, hat den Abschluss einer zusätzlichen ...
Breaking Medicine Technology:Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3
... (Becton, Dickinson and Company) (NYSE: BDX ) announced ... second fiscal quarter 2011 earnings conference call on Wednesday, April ... a press release detailing the quarter,s earnings after the market ... of the conference call, along with related slides, will be ...
... and HOUSTON, April 13, 2011 BD (Becton, Dickinson ... Management Healthcare Solutions, a subsidiary of Waste Management, Inc. ... to recycle medical sharps waste from hospitals and other ... ecoFinity™ Life Cycle Solution, an innovative service that will ...
Cached Medicine Technology:BD and Waste Management Launch Initiative to Recycle Medical Sharps 2BD and Waste Management Launch Initiative to Recycle Medical Sharps 3BD and Waste Management Launch Initiative to Recycle Medical Sharps 4
(Date:9/30/2014)... 2014(BRONX, NY)Medications are the leading cause of allergy-related sudden ... death certificates from 1999 to 2010, conducted by researchers ... Albert Einstein College of Medicine of Yeshiva University . ... of Allergy and Clinical Immunology , also found that ... high among older people and African-Americans and that such ...
(Date:9/30/2014)... Fat Burning Kitchen , the latest diet guide ... that is helping people learn the truth about so-called health ... in less than 24 hours has caught the attention of ... culture that is becoming so obsessed with diets and weight ... fact and fiction when it comes to health foods, eating ...
(Date:9/30/2014)... For most families, fall means back-to-school pictures ... or annual festival. For millions of children, fall also ... respiratory infection Enterovirus D68. , While symptoms mimic ... – especially children with weakened immune systems – can ... is prompting hospitals across the country to enact visitor ...
(Date:9/30/2014)... A group of Americans is headed to a ... left unchecked, could create a catastrophic, global pandemic. No, it’s ... John Rogers, the Executive Director the Eugene Bell Foundation and ... disease most think mankind conquered long ago: tuberculosis. , “Tuberculosis, ... on the comeback in several countries - what’s especially disconcerting ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Medicare should cover low-dose computed ... for the disease, a coalition of more than 60 ... includes the Lung Cancer Alliance, the Society of Thoracic ... Society and the American Society of Clinical Oncology, made ... U.S. Centers for Medicare & Medicaid Services (CMS). ...
Breaking Medicine News(10 mins):Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:As Hospitals Combat Enterovirus Outbreaks, Patients and Families Turn to “Virtual Visits” with CaringBridge 2Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... Goldring, a 61-year-old woman who gradually lost her eyesight to ... to create// a "seeing machine" that will enable her and ... ,The idea was born when Ms Goldring was examined ... read a word for the first time in a few ...
... anti-quota stir as they prayed to God to bless ... elite educational institutions, with wisdom. ,Junior doctors ... and Government Medical College went to Mansa Devi shrine ... give "wisdom" to those at the helm of affairs, ...
... of people having HIV/AIDS as well as tuberculosis in ... ,Launching the National TB/HIV Policy and Communication ... Health Services said that the integration of both diseases ... probably the reason TB is the leading cause of ...
... who undergo lung transplants suffer from rejection of ... have found that inhaled anti-rejection drug, cyclosporine significantly ... The study results were presented at the American ... the same study that previously found that inhaled ...
... novel study has revealed that the proton pump ... maintaining normal gastric acid levels// in those patients ... (IGH). ,Zollinger-Ellison syndrome (ZES), a rare ... development of a tumor or tumors that secrete ...
... thought that, people who actually face tough times in life, ... a startling study has revealed exactly// the contrary. A finding ... are the ones who are vulnerable to deception rather than ... study in the University's School of Psychology found that rather ...
Cached Medicine News:Health News:Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients 2Health News:Is Nexium? beneficial for patients with Zollinger-Ellison syndrome? 2Health News:Take it if you can - Tough Times in Life Churn out Greenhorns 2Health News:Take it if you can - Tough Times in Life Churn out Greenhorns 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: